NAV

Clofibrate

Identification

Summary

Clofibrateis a fibric acid derivative used to treat hypertriglyceridemia and high cholesterol.

总的来说ic Name
Clofibrate
DrugBank Accession Number
DB00636
Background

A fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)

Type
Small Molecule
Groups
Approved, Investigational
Structure
 3D
Similar Structures
Weight
Average: 242.699
Monoisotopic: 242.070972053
Chemical Formula
C12H15ClO3
Synonyms
  • 2-(4-Chlorophenoxy)-2-methylpropanoic acid ethyl ester
  • 2-(p-Chlorophenoxy)-2-methylpropionic acid ethyl ester
  • alpha-(p-Chlorophenoxy)isobutyric acid, ethyl ester
  • alpha-p-Chlorophenoxyisobutyryl ethyl ester
  • Clofibrate
  • Clofibrato
  • Clofibratum
  • EPIB
  • 乙2-(p-chlorophenoxy)isobutyrate
  • 乙chlorophenoxyisobutyrate
  • 乙clofibrate
  • Liprin
External IDs
  • AY-61123
  • ICI 28257
  • ICI-28257
  • NSC-79389

Pharmacology

Indication

For Primary Dysbetalipoproteinemia (Type III hyperlipidemia) that does not respond adequately to diet. This helps control high cholesterol and high triglyceride levels.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Clofibrate is an antilipidemic agent similar to gemfibrozil. It acts to lower elevated serum lipids by reducing the very low-density lipoprotein fraction (Sf20-400) rich in triglycerides. Serum cholesterol may be decreased, particularly in those patients whose cholesterol elevation is due to the presence of IDL as a result of Type III hyperlipoproteinemia. Several investigators have observed in their studies that clofibrate may produce a decrease in cholesterol linoleate but an increase in palmitoleate and oleate, the latter being considered atherogenic in experimental animals. The significance of this finding is unknown at this time. Reduction of triglycerides in some patients treated with clofibrate or certain of its chemically and clinically similar analogs may be associated with an increase in LDL cholesterol. Increase in LDL cholesterol has been observed in patients whose cholesterol is initially normal. Animal studies suggest that clofibrate interrupts cholesterol biosynthesis prior to mevalonate formation.

Mechanism of action

Clofibrate increases the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL. This is accompanied by a slight increase in secretion of lipids into the bile and ultimately the intestine. Clofibrate also inhibits the synthesis and increases the clearance of apolipoprotein B, a carrier molecule for VLDL. Also, as a fibrate, Clofibrate is an agonist of the PPAR-α receptor[4] in muscle, liver, and other tissues. This agonism ultimately leads to modification in gene expression resulting in increased beta-oxidation, decreased triglyceride secretion, increased HDL, increased lipoprotein lipase activity.

Target Actions Organism
APeroxisome proliferator-activated receptor alpha
agonist
 Humans
Absorption

Completely but slowly absorbed from the intestine. Between 95% and 99% of an oral dose of clofibrate is excreted in the urine as free and conjugated clofibric acid; thus, the absorption of clofibrate is virtually complete.

Volume of distribution

Not Available

Protein binding

Highly protein-bound (95% to 97%).

Metabolism

Hepatic and gastrointestinal: rapid de-esterification occurs in the gastrointestinal tract and/or on first-pass metabolism to produce the active form, clofibric acid (chlorophenoxy isobutyric acid [CPIB]).

Route of elimination

Not Available

Half-life

Half-life in normal volunteers averages 18 to 22 hours (range 14 to 35 hours) but can vary by up to 7 hours in the same subject at different times.

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Oral, mouse: LD50= 1220 mg/kg; Oral, rabbit: LD50= 1370 mg/kg; Oral, rat: LD50= 940 mg/kg. No reported case of overdosage in humans.

Pathways
Not Available
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
Integrate drug-drug
interactions in your software
Abametapir The serum concentration of Clofibrate can be increased when it is combined with Abametapir.
Abemaciclib The metabolism of Abemaciclib can be increased when combined with Clofibrate.
Acalabrutinib The metabolism of Acalabrutinib can be increased when combined with Clofibrate.
Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Clofibrate.
Acetaminophen Clofibrate may increase the hepatotoxic activities of Acetaminophen.
Acetohexamide The risk or severity of hypoglycemia can be increased when Clofibrate is combined with Acetohexamide.
Acipimox The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Acipimox.
Albendazole The metabolism of Albendazole can be increased when combined with Clofibrate.
Alectinib The metabolism of Alectinib can be increased when combined with Clofibrate.
Alendronic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Clofibrate.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Take with food. Food decreases the risk of GI side effects.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Alufibrate (The Central)/Atromid-S/Binograc (Kotobuki Seiyaku)/Clobrate (Johnson)/ELPI/Hisunsero (Newai Chem)/Koliva (Golden Horse)/Lipofacton/Myanlin (Sinton)
Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image
Atromid S Cap 500mg Capsule 500 mg / cap Oral Ayerst Laboratories 1968-12-31 1997-08-15 Canada flag
Atromid-S 1gm Capsule 1 g / cap Oral Wyeth Ayerst Canada Inc. 1994-12-31 1998-10-20 Canada flag
Atromid-S Cap 500mg Capsule 500 mg / cap Oral Wyeth Ayerst Canada Inc. 1996-10-25 2000-08-02 Canada flag
总的来说ic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image
Novo-fibrate Cap 500mg Capsule 500 mg / cap Oral Novopharm Limited 1976-12-31 2005-08-10 Canada flag

Categories

ATC Codes
C10AB01 — Clofibrate
Drug Categories
Chemical TaxonomyProvided byClassyfire
Description
This compound belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenoxyacetic acid derivatives
Direct Parent
Phenoxyacetic acid derivatives
Alternative Parents
Phenoxy compounds/Phenol ethers/Chlorobenzenes/Alkyl aryl ethers/Aryl chlorides/Carboxylic acid esters/Monocarboxylic acids and derivatives/Organochlorides/Organic oxides/Hydrocarbon derivatives
show 1 more
Substituents
Alkyl aryl ether/Aromatic homomonocyclic compound/Aryl chloride/Aryl halide/Carbonyl group/Carboxylic acid derivative/Carboxylic acid ester/Chlorobenzene/Ether/Halobenzene
show 10 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
ethyl ester, aromatic ether, monochlorobenzenes (CHEBI:3750)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
HPN91K7FU3
CAS number
637-07-0
InChI Key
KNHUKKLJHYUCFP-UHFFFAOYSA-N
InChI
InChI=1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3
IUPAC Name
ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
SMILES
CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1

References

Synthesis Reference

Jones, W.G.M.,Thorp, J.M. and Waring, W.S.; U.S. Patent 3,262,850; July 26, 1966; assigned to Imperial Chemical Industries Limited, England.
总的来说al References
Not Available
Human Metabolome Database
HMDB0014774
KEGG Drug
D00279
KEGG Compound
C06916
PubChem Compound
2796
PubChem Substance
46504748
ChemSpider
2694
BindingDB
50085047
RxNav
2594
ChEBI
3750
ChEMBL
CHEMBL565
ZINC
ZINC000000056648
Therapeutic Targets Database
DAP000262
PharmGKB
PA449045
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Clofibrate
MSDS
Download (62.6 KB)

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
3 Completed Prevention Cardiovascular Disease (CVD)/Coronary Heart Disease (CHD)/Myocardial Infarction/Myocardial Ischemia 1
Not Available Completed Prevention Cardiovascular Disease (CVD)/Coronary Heart Disease (CHD)/Myocardial Infarction/Myocardial Ischemia 1

Pharmacoeconomics

Manufacturers
  • Wyeth ayerst laboratories
  • Banner pharmacaps inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Usl pharma inc
  • Watson laboratories inc
Packagers
  • Banner Pharmacaps Inc.
  • Major Pharmaceuticals
  • Novopharm Ltd.
Dosage Forms
Form Route Strength
Capsule Oral 1 g / cap
Capsule Oral
Capsule Oral 500 mg / cap
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Property Value Source
melting point (°C) 118-119 Jones, W.G.M.,Thorp, J.M. and Waring, W.S.; U.S. Patent 3,262,850; July 26, 1966; assigned to Imperial Chemical Industries Limited, England.
boiling point (°C) 149 °C at 2.00E+01 mm Hg PhysProp
water solubility Insoluble Not Available
logP 3.3 Not Available
Predicted Properties
Property Value Source
Water Solubility 0.029 mg/mL ALOGPS
logP 3.99 ALOGPS
logP 3.4 Chemaxon
logS -3.9 ALOGPS
pKa (Strongest Basic) -4.9 Chemaxon
Physiological Charge 0 Chemaxon
Hydrogen Acceptor Count 2 Chemaxon
Hydrogen Donor Count 0 Chemaxon
Polar Surface Area 35.53 Å2 Chemaxon
Rotatable Bond Count 5 Chemaxon
Refractivity 62.14 m3·mol-1 Chemaxon
Polarizability 24.7 Å3 Chemaxon
Number of Rings 1 Chemaxon
Bioavailability 1 Chemaxon
Rule of Five Yes Chemaxon
Ghose Filter Yes Chemaxon
Veber's Rule Yes Chemaxon
MDDR-like Rule No Chemaxon
Predicted ADMET Features
Property Value Probability
Human Intestinal Absorption + 1.0
Blood Brain Barrier + 0.9329
Caco-2 permeable + 0.717
P-glycoprotein substrate Non-substrate 0.589
P-glycoprotein inhibitor I Non-inhibitor 0.7133
P-glycoprotein inhibitor II Non-inhibitor 0.8544
Renal organic cation transporter Non-inhibitor 0.8868
CYP450 2C9 substrate Non-substrate 0.8517
CYP450 2D6 substrate Non-substrate 0.9116
CYP450 3A4 substrate Substrate 0.6692
CYP450 1A2 substrate Inhibitor 0.9107
CYP450 2C9 inhibitor Non-inhibitor 0.9071
CYP450 2D6 inhibitor Non-inhibitor 0.9231
CYP450 2C19 inhibitor Non-inhibitor 0.9026
CYP450 3A4 inhibitor Non-inhibitor 0.8861
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.5832
Ames test Non AMES toxic 0.9132
Carcinogenicity Non-carcinogens 0.5492
Biodegradation Not ready biodegradable 0.9711
Rat acute toxicity 2.3806 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9891
hERG inhibition (predictor II) Non-inhibitor 0.8735
ADMET data is predicted usingadmetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.78 KB)
Spectra
Spectrum Spectrum Type Splash Key
Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Mass Spectrum (Electron Ionization) MS splash10-004i-3900000000-fc2f01df51d424557e9f
Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets tounlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details 1.Peroxisome proliferator-activated receptor alpha
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
总的来说al Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleyleth...
Gene Name
PPARA
Uniprot ID
Q07869
Uniprot Name
Peroxisome proliferator-activated receptor alpha
分子量
52224.595 Da
References
  1. Barclay TB, Peters JM, Sewer MB, Ferrari L, Gonzalez FJ, Morgan ET: Modulation of cytochrome P-450 gene expression in endotoxemic mice is tissue specific and peroxisome proliferator-activated receptor-alpha dependent. J Pharmacol Exp Ther. 1999 Sep;290(3):1250-7. [Article]
  2. Murata M, Kaji H, Takahashi Y, Iida K, Mizuno I, Okimura Y, Abe H, Chihara K: Stimulation by eicosapentaenoic acids of leptin mRNA expression and its secretion in mouse 3T3-L1 adipocytes in vitro. Biochem Biophys Res Commun. 2000 Apr 13;270(2):343-8. [Article]
  3. Hunt MC, Lindquist PJ, Peters JM, Gonzalez FJ, Diczfalusy U, Alexson SE: Involvement of the peroxisome proliferator-activated receptor alpha in regulating long-chain acyl-CoA thioesterases. J Lipid Res. 2000 May;41(5):814-23. [Article]
  4. Casas F, Domenjoud L, Rochard P, Hatier R, Rodier A, Daury L, Bianchi A, Kremarik-Bouillaud P, Becuwe P, Keller J, Schohn H, Wrutniak-Cabello C, Cabello G, Dauca M: A 45 kDa protein related to PPARgamma2, induced by peroxisome proliferators, is located in the mitochondrial matrix. FEBS Lett. 2000 Jul 28;478(1-2):4-8. [Article]
  5. Komuves LG, Hanley K, Lefebvre AM, Man MQ, Ng DC, Bikle DD, Williams ML, Elias PM, Auwerx J, Feingold KR: Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol. 2000 Sep;115(3):353-60. [Article]
  6. Gelosa P, Banfi C, Gianella A, Brioschi M, Pignieri A, Nobili E, Castiglioni L, Cimino M, Tremoli E, Sironi L: Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats. J Pharmacol Exp Ther. 2010 Nov;335(2):324-31. doi: 10.1124/jpet.110.171090. Epub 2010 Jul 29. [Article]
  7. Palkar PS, Anderson CR, Ferry CH, Gonzalez FJ, Peters JM: Effect of prenatal peroxisome proliferator-activated receptor alpha (PPARalpha) agonism on postnatal development. Toxicology. 2010 Sep 30;276(1):79-84. doi: 10.1016/j.tox.2010.07.008. Epub 2010 Jul 15. [Article]

Enzymes

Details 1.Cytochrome P450 1A1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
总的来说al Function
维生素d 24-hydroxylase活动
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
分子量
58164.815 Da
References
  1. Lee PC, Marquardt M, Lech JJ: Metabolism of nonylphenol by rat and human microsomes. Toxicol Lett. 1998 Oct 15;99(2):117-26. doi: 10.1016/s0378-4274(98)00153-2. [Article]
  2. Seree E, Villard PH, Pascussi JM, Pineau T, Maurel P, Nguyen QB, Fallone F, Martin PM, Champion S, Lacarelle B, Savouret JF, Barra Y: Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45. doi: 10.1053/j.gastro.2004.08.023. [Article]
  3. Rey-Grobellet X, Eeckhoutte C, Sutra JF, Alvinerie M, Galtier P: Major involvement of rabbit liver cytochrome P4501A in thiabendazole 5-hydroxylation. Xenobiotica. 1996 Jul;26(7):765-78. [Article]
Details 2.Cytochrome P450 4A11
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inducer
总的来说al Function
Leukotriene-b4 20-monooxygenase activity
Specific Function
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 2...
Gene Name
CYP4A11
Uniprot ID
Q02928
Uniprot Name
Cytochrome P450 4A11
分子量
59347.31 Da
References
  1. 李,李D,领带C,吴J,吴问,李问:Cisplatin-mediated cytotoxicity through inducing CYP4A 11 expression in human renal tubular epithelial cells. J Toxicol Sci. 2015 Dec;40(6):895-900. doi: 10.2131/jts.40.895. [Article]
  2. Raucy JL, Lasker J, Ozaki K, Zoleta V: Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol Sci. 2004 Jun;79(2):233-41. doi: 10.1093/toxsci/kfh126. Epub 2004 Mar 31. [Article]
  3. Savas U, Machemer DE, Hsu MH, Gaynor P, Lasker JM, Tukey RH, Johnson EF: Opposing roles of peroxisome proliferator-activated receptor alpha and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model. J Biol Chem. 2009 Jun 12;284(24):16541-52. doi: 10.1074/jbc.M902074200. Epub 2009 Apr 14. [Article]
Details 3.Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inducer
总的来说al Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
分子量
57342.67 Da
References
  1. Donato MT, Castell JV, Gomez-Lechon MJ: Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metab Dispos. 1995 May;23(5):553-8. [Article]
  2. Miller DB, Spence JD: Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62. doi: 10.2165/00003088-199834020-00003. [Article]
Details 4.Glutathione S-transferase A2
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
总的来说al Function
Glutathione transferase activity
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
Gene Name
GSTA2
Uniprot ID
P09210
Uniprot Name
Glutathione S-transferase A2
分子量
25663.675 Da
References
  1. Foliot A, Touchard D, Mallet L: Inhibition of liver glutathione S-transferase activity in rats by hypolipidemic drugs related or unrelated to clofibrate. Biochem Pharmacol. 1986 May 15;35(10):1685-90. [Article]
  2. Foliot A, Touchard D, Celier C: Impairment of hepatic glutathione S-transferase activity as a cause of reduced biliary sulfobromophthalein excretion in clofibrate-treated rats. Biochem Pharmacol. 1984 Sep 15;33(18):2829-34. [Article]
Details 5.Cytochrome P450 2E1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
总的来说al Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
分子量
56848.42 Da
References
  1. Lee PC, Marquardt M, Lech JJ: Metabolism of nonylphenol by rat and human microsomes. Toxicol Lett. 1998 Oct 15;99(2):117-26. doi: 10.1016/s0378-4274(98)00153-2. [Article]
  2. Adas F, Berthou F, Picart D, Lozac'h P, Beauge F, Amet Y: Involvement of cytochrome P450 2E1 in the (omega-1)-hydroxylation of oleic acid in human and rat liver microsomes. J Lipid Res. 1998 Jun;39(6):1210-9. [Article]

Carriers

Details 1.Thyroxine-binding globulin
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inducer
总的来说al Function
Serine-type肽链内切酶抑制剂活性
Specific Function
Major thyroid hormone transport protein in serum.
Gene Name
SERPINA7
Uniprot ID
P05543
Uniprot Name
Thyroxine-binding globulin
分子量
46324.12 Da
References
  1. CYTOMEL (liothyronine) FDA label [File]

Drug created at June 13, 2005 13:24 / Updated at March 03, 2023 17:36